Tom Lynch (Rob Tannenbaum, Endpoints News)
July 14, 2021 04:54 PM EDT
R&D

Tom Lynch moves to re­struc­ture Fred Hutch as acad­e­mia, in­dus­try con­tin­ue to push cell ther­a­py in­to sol­id tu­mors

Jason Mast

Editor

By the time for­mer Bris­tol My­ers Squibb CSO Tom Lynch stepped in to run the Fred Hutch Can­cer Re­search Cen­ter last year, both the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Ex-Kite lead­ers step in at Kyver­na as CEO ex­its af­ter land­ing year's sec­ond-biggest IPO

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

BioN­Tech rolls out Phase 2 lung can­cer da­ta as VEGF bis­pecifics take cen­ter stage

Im­mat­ics los­es Bris­tol My­er­s' sup­port on Phase 1 bis­pe­cif­ic T cell en­gager

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times